Vision Medicals Closed on 100 Million Yuan A Round of Financing, Led By Volcanics Venture and CASH Capital

According to VCBeat, on September 11, 2019, Vision Medicals announced that it had completed A round of financing of 100 million yuan, led by Volcanics Venture and CASH Capital.

In recent years, except for precision medical technology in reproductive health and tumor diagnosis, infection pathogen diagnosis has been developed. The emergence of new technologies, such as pathogen metagenomics based on high-throughput sequencing and rapid diagnosis based on CRISPR, has effectively improved the detection ability of clinical pathogens, shortened the reporting cycle, and accelerated the development of the precision medicine industry for infection.

Vision Medicals focuses on precise medical treatment of infection. It has nearly 3000 square meters of medical laboratory, R&D center, and GMP workshop. The company has two core products, including pathogen metagenomics platform IDseqTM and pathogen CRISPR rapid diagnosis platform ID- CRISPRTM.

This round of financing will be used for three aspects:

1. R&D Investment: To optimize and upgrade pathogenic metagenomics products and gene editing rapid diagnosis products.

2. Registration Application: To accelerate the registration inspection and clinical trial of the first pathogen metagenomics product.

3. Clinical Cooperation: To work with medical laboratories and top-grade three first-class hospitals and jointly build innovative platforms.

Volcanics Venture was founded in May 2016. It invests in the most promising companies and outstanding entrepreneurs in Internet Innovation, Intelligent Technology, and Healthcare industry.

Volcanics Venture brings a powerful combination of global perspective and local experience to investment management, striving to provide sustainable value-added service to their portfolio companies and bring superior returns to their limited partners.

CASH Capital mainly invests in emerging industries such as six major areas, including smart manufacturing, mobile Internet and services, big data and artificial intelligence, financial technology, medical services, medical devices and pharmaceuticals. The company focuses on fast-growing businesses in the start-up and growth stages.